Recent News for MIST - Milestone Pharmaceuticals Inc.

Date Title
Apr 2 Milestone Pharmaceuticals Stock Is a Bet On Etripamil
Mar 29 Milestone Pharmaceuticals EPS beats by $0.18
Mar 29 Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update
Mar 29 Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate
Mar 5 Benzinga's Top Ratings Upgrades, Downgrades For March 5, 2021
Feb 1 How Much Of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Do Institutions Own?
Dec 3 Is Milestone Pharmaceuticals (MIST) A Good Stock To Buy Now?
Nov 23 Government of Canada Creates Task Force on Flood Insurance and Relocation
Nov 18 First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT
Nov 18 Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
Nov 13 Milestone Pharmaceuticals EPS beats by $0.09
Nov 13 Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update
Nov 11 Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Oct 23 The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Oct 23 Milestone Pharma down 18% after pricing $45M equity offering
Oct 23 Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants
Oct 22 Milestone Pharmaceuticals launches equity offering
Oct 22 Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Back to the Main MIST Page...